The EPiC trial
This clinical trial aims to demonstrate the clinical and cost-utility of High-Flow Therapy (HFT), assessing the viability of home HFT as a suitable therapy for patients that have previously been hospitalised due to severe Chronic Obstructive Pulmonary Disease (COPD) exacerbation.
Main inclusion criteria
• Patients admitted to hospital with an exacerbation of COPD
• Age 40-80 years with smoking history >10 pack years
• Patient’s forced expiratory volume in 1 second (FEV1) is <80% predicted
• Patient’s FEV1/forced vital capacity (FVC) < 0.7
Prospective, multicentre, open-label, randomised, controlled trial with parallel groups.
Prof Nicholas Hart
Dr Patrick Murphy
Lane Fox Clinical Respiratory Physiology, Research Centre, St Thomas Hospital
Guy’s and St Thomas’ Hospital NHS Foundation Trust
502 patients randomised into two groups:
• Intervention: Usual care + Home HFT
• Control: Usual care
The enrolment period will last 24 months, with a follow-up period of 12 months, for a total study duration of 36 months.
14 proposed centres
Learn more: Home HFT for COPD
Home high-flow therapy for COPD
Learn how HFT could be indicated for home use in COPD patients experiencing secretion management issues.
Webinars on home high-flow therapy
Experts explain the evidence for using HFT in different indications, discuss current research gaps and explore the potential benefits of this emerging therapy.
This content is intended for health professionals only
* For more information visit the investigator’s research page https://www.kcl.ac.uk/research/epic-hft
** CAT, computerised adaptive tests; PSQI, Pittsburgh sleep quality index; EQ-5D-5L, EuroQol 5-dimension, 5-level quality of life questionnaire.